Capecitabine-induced coronary vasospasm--a case report.
The authors report the case of a 70-year-old man with metastatic colon cancer and no known history of coronary disease or major risk factors who developed coronary vasospasm after the initiation of capecitabine (Xeloda). Although coronary vasospasm has been associated with another older fluoropyrimidine compound, 5-fluorouracil, this is the first reported occurrence with this relatively newer cancer drug.
Rizvi
Asad A
AA
Division of Cardiology, Department of Medicine, Hartford Hospital, Hartford, CT, USA.
Schauer
Peter
P
Owlia
Dariush
D
Kallal
James E
JE
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D000069287:Capecitabine; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000473:pathology; D003329:Coronary Vasospasm / Q000139:chemically induced*; D003841:Deoxycytidine / Q000009:adverse effects* / Q000031:analogs & derivatives*; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D008297:Male
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil